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Abstract
Rationale — Acute antipsychotic treatment disrupts condi-
tioned avoidance responding, and repeated treatment in-
duces a sensitization- or tolerance-like effect. However, the 
neurochemical mechanisms underlying both acute and re-
peated antipsychotic effects remain to be determined. 
Objective — The present study examined the neuroreceptor 
mechanisms of haloperidol, clozapine, and olanzapine effect 
in a rat two-way conditioned avoidance model. 
Methods — Well-trained Sprague–Dawley rats were adminis-
tered with haloperidol (0.05 mg/kg, sc), clozapine (10.0 mg/
kg, sc), or olanzapine (1.0 mg/kg, sc) together with either sa-
line, quinpirole (a selective dopamine D2/3 agonist, 1.0 mg/
kg, sc), or 2,5-dimethoxy-4-iodo-amphetamine (DOI; a selec-
tive 5-HT2A/2C agonist, 2.5 mg/kg, sc), and their conditioned 
avoidance responses were tested over 3 days. After 2 days 
of drug-free retraining, the repeated treatment effect was as-
sessed in a challenge test. 
Results — Pretreatment of quinpirole, but not DOI, attenuated 
the acute haloperidol-induced disruption of avoidance re-
sponding and to a lesser extent, olanzapine-induced disrup-
tion. In contrast, pretreatment of DOI, but not quinpirole, at-
tenuated the acute effect of clozapine. On the repeated effect, 
pretreatment of DOI, but not quinpirole, attenuated the po-
tentiated disruption of haloperidol, whereas pretreatment of 
quinpirole attenuated the potentiated disruption of olanzap-
ine but enhanced the tolerance-like effect of clozapine. 
Conclusions — These findings suggest that acute haloperidol 
and olanzapine disrupt avoidance responding primarily by 
blocking dopamine D2 receptors, whereas acute clozapine 
exerts its disruptive effect primarily by blocking the 5-HT2A 
receptors. The repeated haloperidol effect may be mediated 
by 5-HT2A/2C blockade-initiated neural processes, whereas 
the repeated clozapine and olanzapine effect may be medi-
ated by D2/3 blockade-initiated neural processes. 
Keywords:  Haloperidol, Clozapine, Olanzapine, Quinpirole, 
2,5-dimethoxy-4-iodo-amphetamine, Repeated antipsychotic 
treatment, Conditioned avoidance response, Sensitization, 
Tolerance 
Introduction
The conditioned avoidance response model (CAR) 
is a fear-motivated instrumental conditioning model 
which is traditionally used in behavioral pharmacol-
ogy as a preclinical screen for antipsychotic activity 
(Bolles 1970; Levis and Brewer 2001; Rescorla and Sol-
omon 1967). In this model, acute treatment of antipsy-
chotic drugs selectively disrupts avoidance respond-
ing without altering unconditioned escape response 
(Arnt 1982; Wadenberg et al. 2001b). Recently, we have 
expanded the use of this model to identify the behav-
ioral mechanisms of action of antipsychotic drugs (Li 
et al. 2007; Li et al. 2009a,b; Mead and Li 2009) and to 
examine the anxiolytic property of atypical antipsy-
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chotic drugs (Mead et al. 2008). It is suggested that un-
derstanding the nature of the avoidance deficit induced 
by antipsychotics may shed light on how antipsychotic 
drugs achieve their clinical efficacy in the treatment of 
psychosis (Li et al. 2009b). 
Although the avoidance disruptive effect of antipsy-
chotic treatment is robust and well-documented, the 
neuroreceptor basis of this action is less clear. It has 
also not been determined whether typical and atypi-
cal antipsychotics differ in their neurochemical mech-
anisms in this model (Wadenberg and Hicks 1999). 
For typical antipsychotics such as haloperidol (HAL), 
it is generally assumed (but not proven) that they dis-
rupt avoidance behavior by blocking dopamine D2 re-
ceptors because they are primarily dopamine D2 an-
tagonists (Dragunow et al. 1990; Seeman et al. 1976). In 
contrast, atypical antipsychotics (e.g., clozapine, olan-
zapine) have multiple-receptor binding sites (Meltzer 
et al. 1989; Miyamoto et al. 2005), making it more diffi-
cult to pinpoint their exact neurochemical mechanisms 
relevant to their CAR effects. Both clozapine (CLZ) and 
olanzapine (OLZ) possess a much more potent antag-
onism on the 5-HT2A/2C receptor in addition to rela-
tively weak antagonism on D2 receptor (Meltzer et al. 
2003). It is thus possible that their disruptive effect on 
CAR could be attributed to their action on D2 recep-
tor alone (Kapur and Seeman 2001; Wadenberg et al. 
2001b) or its dual action on both 5-HT2A/2C and D2 re-
ceptor (Meltzer et al. 1989) or even effects on other re-
ceptors (e.g. D1, D4, 5-HT1A). 
In the present study, we took a pharmacological ap-
proach to delineate the neuroreceptor mechanisms of 
HAL, CLZ, and OLZ in a two-way CAR model. We ex-
amined how the avoidance disruptive effect of these 
drugs was affected by pretreatments of quinpirole 
(QUI), a selective D2/D3 dopaminergic receptor agonist 
and/or 2,5-dimethoxy-4-iodo-amphetamine (DOI), a se-
lective 5-HT2A/2C serotonergic receptor agonist. We re-
cently applied a similar approach in a rat maternal be-
havior model and found that pretreatment of QUI, but 
not DOI, dose-dependently reversed the HAL-induced 
disruptions on active maternal responses, whereas pre-
treatment of DOI, but not QUI, dose-dependently re-
versed the CLZ-induced disruptions (Zhao and Li 2009). 
Based on these findings and the receptor binding pro-
files of each antipsychotic (Miyamoto et al. 2005), we hy-
pothesized that QUI, but not DOI, is able to attenuate 
the HAL-induced disruption on CAR and may also be 
effective in alleviating the OLZ-induced disruption to 
some extent. In contrast, DOI, but not QUI, is able to at-
tenuate the CLZ-induced disruption on CAR and may 
also be effective in alleviating the OLZ-induced dis-
ruption to some extent. One additional experiment ad-
dressed the specificity of the reversal effects of QUI and 
DOI on avoidance responding and its relation to their 
psychomotor stimulating effects. 
In our previous studies (Li et al. 2007, 2009a,b; Mead 
and Li 2009), we found that repeated antipsychotic treat-
ment can produce a long-term change in its disruptive 
effect on avoidance responding. For example, rats pre-
viously treated with HAL and OLZ made significantly 
less avoidances than those who were treated with these 
drugs for the first time (Mead and Li 2009). This finding 
indicates that repeated antipsychotic treatment may in-
duce a sensitization-like effect. However, we know al-
most nothing about the neuroreceptor mechanisms un-
derlying this repeated drug effect in the avoidance 
conditioning model. In the present study, we also exam-
ined how this long-term repeated effect was affected by 




Male Sprague–Dawley rats (226–250 g upon ar-
rival, Charles River, Portage, MI) were housed two per 
cage, in 48.3 × 26.7 × 20.3 cm transparent polycarbon-
ate cages under 12-h light/dark conditions (light on be-
tween 6:30 a.m. and 6:30 p.m.). Room temperature was 
maintained at 22 ± 1° with a relative humidity of 55–
60%. Food and water were available ad libitum. An-
imals were allowed at least 1 week of habituation to 
the animal facility before being used in experiments. 
All procedures were approved by the Institutional An-
imal Care and Use Committee at the University of 
Nebraska-Lincoln. 
Two-way avoidance conditioning apparatus
Eight identical two-way shuttle boxes cus-
tom designed and manufactured by Med Associ-
ates (St. Albans, VT) were used. Each box was housed 
in a ventilated, sound-insulated isolation cubicle 
(96.52 cm W × 35.56 cm D × 63.5 cm H). Each box was 
64 cm long, 30 cm high (from grid floor), and 24 cm 
wide, and was divided into two equal-sized compart-
ments by a partition with an arch style doorway (15 cm 
high × 9 cm wide at base). A barrier (4 cm high) was 
placed between the two compartments, so the rats had 
to jump from one compartment to the other. The grid 
floor consisted of 40 stainless-steel rods with a diameter 
of 0.48 cm, spaced 1.6 cm apart center to center, through 
which a scrambled footshock (US, 0.8 mA, maximum 
duration: 5 s) was delivered by a constant current shock 
generator (Model ENV-410B) and scrambler (Model 
ENV-412). The rat location, motor activity (photobeam 
breaks), and crossings between compartments were 
monitored by a set of 16 photobeams (ENV-256-8P) af-
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fixed at the bottom of the box (3.5 cm above the grid 
floor). Illumination was provided by two houselights 
mounted at the top of each compartment. The CS (i.e., 
76 dB white noise) was produced by a speaker (ENV 
224 AMX) mounted on the ceiling of the cubicle, cen-
tered above the shuttle box. Background noise (approxi-
mately 74 dB) was provided by a ventilation fan affixed 
at the top corner of each isolation cubicle. All training 
and testing procedures were controlled by Med Associ-
ates programs running on a computer. 
Drugs
The injection solution of HAL (5.0 mg/ml am-
poules, Shanghai Xudong Haipu Pharmaceutical Co., 
Ltd., Shanghai, China) was obtained by mixing drugs 
with sterile water. CLZ and OLZ (gifts from NIMH 
drug supply program) were dissolved in 1.0% gla-
cial acetic acid in distilled water. QUI and DOI (RBI-
Sigma, Natick, MA) were dissolved in 0.9% saline. 
All drugs were administered subcutaneously in a vol-
ume of 1.0 ml/kg body weight. Choices of drug doses 
for HAL, CLZ, and OLZ were based on our previous 
studies showing that at the chosen doses, all three 
drugs produce a reliable and comparable disruption of 
avoidance responding (Li et al. 2004; Li et al. 2009a,b; 
Mead and Li 2009), and they give rise to clinical levels 
of striatal D2 occupancy (50–80%) at these doses (Ka-
pur et al. 2003). The doses of QUI and DOI were cho-
sen based on our recent maternal behavior work show-
ing that QUI 1.0 mg/kg was effective in reversing the 
HAL-induced disruptions of active maternal behaviors 
and that DOI 2.5 mg/kg was effective in reversing the 
CLZ-induced disruptions of maternal behaviors (Zhao 
and Li 2009). Previous work also showed that DOI pro-
duces maximal behavioral effects between 2 and 3 mg/
kg (Granoff and Ashby 1998; Halberstadt et al. 2009; 
Schreiber et al. 1995). 
Experiment 1: Effects of QUI pretreatment on  
HAL- and CLZ-induced avoidance disruption
Sixty rats were first habituated to the two-way CAR 
boxes for 2 days (20 min/day). Then, they were trained 
for conditioned avoidance responding for ten sessions 
over a 2-week period. Each session consisted of 30 tri-
als. Every trial started by presenting the white noise 
(CS) for 10 s, followed by a continuous scrambled foot-
shock (0.8 mA, US, maximum duration = 5 s) on the grid 
floor. If a subject moved from one compartment into the 
other within the 10 s of CS presentation, it avoided the 
shock and this shuttling response was recorded as avoid-
ance. If the rat remained in the same compartment for 
more than 10 s and made a crossing upon receiving the 
footshock, this response was recorded as escape. If the 
rat did not respond during the entire 5 s presentation of 
the shock, the trial was terminated and escape failure was 
recorded. Intertrial intervals varied randomly between 
30 and 60 s. The number of avoidance responses was 
recorded. 
At the end of the training session, 46 rats reached the 
training criterion (>70% avoidance in each of the last 
two sessions. Their averaged number of avoidances on 
the last training day (mean) = 29.17, SE = 0.18). They 
were first matched on avoidance performance on the 
last training day (i.e., predrug) to create blocks of rats 
(n = 5–6 rats/block) that were approximately equal in 
performance. Within each block, they were then ran-
domly assigned to one of five groups: VEH + VEH 
(n = 10, saline + sterile water), VEH + HAL (n = 9), 
VEH + CLZ (n = 9), QUI + HAL (n = 9), and QUI + CLZ 
(n  = 9), and repeatedly tested daily under the CS-only 
(no shock, 30 trials/session) condition for three con-
secutive days. The CS-only condition was used to con-
trol the possible confound of number of shocks received 
and to exclude any possible relearning effect caused 
by the presence of the US. During each test, rats were 
first pretreated with QUI 1.0 mg/kg (sc) or saline fol-
lowed by an injection of sterile water, HAL 0.05 mg/
kg (sc) or CLZ 10.0 mg/kg (sc) 10 min later. Thirty min-
utes after the second injection, rats were placed in the 
CAR boxes and tested. One day after the end of the 3rd 
test, all rats were tested drug-free for one session un-
der the CS-only (no shock) condition and retrained for 
one session under the CS–US condition to bring their 
avoidance back to the predrug level. A final drug chal-
lenge test was conducted 24 h after the retraining ses-
sion to assess the long-term effect of repeated antipsy-
chotic treatment on avoidance. During the test, rats in 
the VEH + HAL and QUI + HAL groups were injected 
with HAL 0.025 mg/kg, whereas rats in the VEH + CLZ 
and QUI + CLZ groups were injected with CLZ 5.0 mg/
kg. Half of the VEH + VEH rats (n = 5) were injected 
with HAL 0.025 mg/kg and another half (n = 5) were in-
jected with CLZ 5.0 mg/kg. The CS-only test (no US, 30 
trials) was conducted 30 min after the drug injection. 
Experiment 2: Effects of DOI pretreatment on  
HAL- and CLZ-induced avoidance disruption
The basic procedure was identical to that of experi-
ment 1 with the exception that DOI (2.5 mg/kg, sc) pre-
treatment effect was examined. Sixty rats were used, of 
which 45 reached the training criterion (>70% avoid-
ance in each of the last two sessions, mean = 29.16, 
SE = 0.23). Following the group assigning procedure as 
described in experiment 1, they were allocated to the 
following five groups: VEH + VEH (saline + sterile wa-
ter), VEH + HAL (0.05 mg/kg), VEH + CLZ (10.0 mg/
kg), DOI + HAL, and DOI + CLZ, and were subjected to 
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three sessions of drug testing and two sessions of drug-
free testing/retraining and a final drug challenge test, 
following the exact same schedule as described in ex-
periment 1. During the challenge test, four VEH + VEH 
rats were injected with HAL 0.025 mg/kg and five were 
injected with CLZ 5.0 mg/kg. 
Experiment 3: Effects of QUI and DOI pretreatment on 
HAL and CLZ suppressive effect on motor activity in 
the CAR
This experiment was designed to examine the speci-
ficity of the pretreatment effects of QUI and DOI on an-
tipsychotic-induced avoidance disruption. We asked 
whether the reversal effects could be attributed to the 
drug’s effects on motor activity. The basic procedure 
was similar to that used in the above experiments ex-
cept that on the three drug days, rats were only tested 
for their motor activity in the CAR boxes, not for their 
avoidances (i.e., no CS or US was presented). Forty-eight 
rats were trained in ten sessions, of which 34 reached 
learning criterion (mean = 27.88, SE = 0.41). Following 
the group assigning procedure as described in experi-
ment 1, they were allocated to the following five groups: 
VEH + VEH (n = 10, saline + sterile water), VEH + HAL 
(n = 6), QUI + HAL (n = 6), VEH + CLZ (n = 6), and 
DOI + CLZ (n  = 6). Over the next 3 days, 30 min after 
the second injection, they were placed in the CAR boxes 
and motor activity was recorded for 30 min (the approx-
imate time required to complete one CAR session). The 
number of crossings between two compartments was 
also recorded. 
Experiment 4: effects of QUI and DOI pretreatment on 
OLZ-induced avoidance disruption
This experiment examined the receptor mecha-
nisms of acute and repeated effects of OLZ. The basic 
procedure was identical to that of experiments 1 and 
2 with the exception that both QUI (1.0 mg/kg) and 
DOI (2.5 mg/kg) pretreatment effects were examined 
against OLZ (1.0 mg/kg, sc). Sixty rats were trained in 
ten sessions, of which 42 reached the training criterion 
(mean = 28.60, SE = 0.31). Following the group assigning 
procedure as described in experiment 1, they were allo-
cated to the following five groups: VEH + VEH (n = 8, 
saline + sterile water), VEH + OLZ (n = 9), QUI + OLZ 
(n = 8), DOI + OLZ (n = 8), and QUI + DOI + OLZ (n 
= 9), and were subjected to the three sessions of drug 
testing and two sessions of drug-free testing/retraining 
and a final drug challenge test. During the three drug 
testing sessions, rats in the QUI + DOI + OLZ group 
were injected with QUI and DOI first, followed by an in-
jection of OLZ 10 min later. During the drug challenge 
test, all rats were injected with OLZ at 0.5 mg/kg. 
Statistical analysis
The number of avoidance responses and motor activ-
ity data (number of photobeam breaks) were expressed 
as mean ± SEM. Data on the three drug test sessions 
were analyzed using a split-plot analysis of variance 
(ANOVA) with the between-subjects factor being drug 
group and the within-subjects factor being test ses-
sion. To identify group difference on a specific test day, 
one-way ANOVAs followed by post-hoc Tukey’s HSD 
tests (for more than three groups) were used. Indepen-
dent samples t tests were used to examine two-group 
difference in cases where there was a prior research 
hypothesis. 
Results
Experiment 1: Effects of QUI pretreatment on HAL- and 
CLZ-induced avoidance disruption
One rat from the QUI + CLZ group died unexpect-
edly before the retraining and drug challenge test. Its 
data on these two sessions were not analyzed. As can 
be seen in Figure 1, HAL and CLZ suppressed avoid-
ance responding on the first drug day and maintained 
this suppression over the 3 days in comparison to 
the vehicle treatment. A split-plot ANOVA revealed 
a main effect of drug treatment (F(4,41) = 50.271, 
P < 0.001) and a significant treatment × session interac-
tion (F(8,82) = 4.626, P < 0.001), but no significant main 
effect of session (F(2,82) = 2.350, P = 0.102). One-way 
ANOVAs followed by post-hoc tests on each drug test 
day revealed that all drug groups differed significantly 
from the VEH + VEH group (P < 0.001). Post-hoc anal-
ysis showed that on the 1st drug day, the QUI + HAL 
group made significantly more avoidances than the 
VEH + HAL group (P = 0.021), whereas the QUI + CLZ 
group did not differ significantly from the VEH + CLZ 
group (P  = 0.991), suggesting that pretreatment of 
QUI attenuated the HAL-induced disruption of avoid-
ance responding on the 1st day, but did not affect the 
CLZ-induced disruption. This attenuation effect was 
no longer present on the subsequent two drug days (all 
P > 0.10). 
To detail the time course of the attenuation effect of 
QUI, we examined the within-session change of avoid-
ance responding across the three ten-trial blocks on 
day 1 (data not shown). QUI completely reversed the 
effect of HAL in the 1st block, but lost its effect in the 
latter blocks (1st block, VEH + VEH vs. QUI + HAL, 
P = 0.611; QUI + HAL vs. VEH + HAL, P = 0.010. Sec-
ond and third blocks, VEH + VEH vs. QUI + HAL, 
P > 0.13), a finding consistent with QUI’s relatively 
short duration of action (Whitaker and Lindstrom 
1987). 
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HAL- and CLZ-treated rats reinstated their avoid-
ance responding in just two sessions when the drug 
treatments were stopped to a level that was compara-
ble to that of vehicle treatment (Figure 1). On the drug 
challenge test (Figure 2), rats previously treated with 
HAL (i.e., VEH + HAL and QUI + HAL) showed much 
lower avoidance responding than the vehicle rats treated 
with HAL for the first time. However, an opposite pat-
tern was observed in the CLZ challenge condition: the 
CLZ-experienced rats (i.e., VEH + CLZ and QUI + CLZ) 
showed much higher avoidance responding than the ve-
hicle rat treated with CLZ for the first time. One-way 
ANOVA revealed that under the HAL (0.025 mg/kg) 
challenge condition, there was a main effect of group 
(F(2,20) = 3.638, P  = 0.045), and post-hoc tests showed 
that the VEH + HAL rats made significantly fewer 
avoidances than the VEH + VEH ones (HAL-chal-
lenged) (P = 0.039). The QUI + HAL group did not dif-
fer from the VEH + VEH (P = 0.116) nor the VEH + HAL 
(P = 0.795). Under the CLZ (5.0 mg/kg) challenge condi-
tion, there was a main effect of group (F(2,19) = 6.837, P 
= 0.006), and post-hoc tests showed that the QUI + CLZ 
group made significantly more avoidances than the 
VEH + VEH (CLZ-challenged) group (P = 0.005), but 
not significantly more than the VEH + CLZ group 
(P = 0.286). 
Experiment 2: Effects of DOI pretreatment on HAL- and 
CLZ-induced avoidance disruption
Once again, HAL and CLZ suppressed avoidance re-
sponding throughout the drug test period (Figure 3). A 
split-plot ANOVA revealed a main effect of drug treat-
ment (F(4, 40) = 48.301, P < 0.001). One-way ANOVAs 
showed that all drug groups made significantly fewer 
avoidances than the VEH + VEH group on every drug 
test day (P < 0.001). Importantly, the DOI + CLZ group 
made significantly more avoidance than the VEH + CLZ 
group (day 1, P < 0.001; day 2, P = 0.005; and day 3, 
P < 0.001), whereas the DOI + HAL group did not dif-
fer significantly from the VEH + HAL group (day 1, 
P = 0.964; day 2, P = 0.738; and day 3, P = 1.000), sug-
gesting that pretreatment of DOI attenuated the CLZ-in-
duced disruption of avoidance responding, but did not 
affect the HAL-induced disruption. This attenuation ef-
fect was persistent throughout the drug testing days. 
The within-session pattern of avoidance responding 
on the 1st drug day revealed that DOI pretreatment at-
tenuated the avoidance disruptive effect of CLZ (not 
HAL) in the 1st and 2nd 10-trial blocks (Tukey’s HSD 
post-hoc test: DOI + CLZ vs. VEH + CLZ: P < 0.001 
and P = 0.001, respectively), but lost its effect in the last 
block (P = 0.195) (data not shown). A similar pattern 
Figure 1. Effects of pretreatment 
of quinpirole on acute haloperi-
dol and clozapine-induced avoid-
ance disruption. Data are mean 
(+SEM) numbers of avoidance 
responses of the five groups of 
rats on the last CAR training day 
(predrug), three drug test days 
(days 1 to 3) and two drug-free 
test days (drug-free CS-only and 
drug-free retraining). *P < 0.05 
significantly different from the 
VEH + VEH group; #P < 0.05 
significantly different from the 
VEH + HAL group. 
Figure 2. Effects of pretreatment of quinpirole 
on repeated effect of haloperidol and clozapine 
treatment on avoidance responding. Data are 
mean (+SEM) numbers of avoidance responses 
on the challenge test day. Rats that were pre-
viously treated with either double vehicles 
(n = 5), vehicle plus haloperidol (0.05 mg/kg), 
or quinpirole (1.0 mg/kg) plus haloperidol 
(0.05 mg/kg) were challenged with haloperi-
dol (0.025 mg/kg). Rats that were previously 
treated with either double vehicles (n = 5), ve-
hicle plus clozapine (10.0 mg/kg), or quin-
pirole (1.0 mg/kg) plus clozapine (10.0 mg/
kg) were challenged with clozapine (5.0 mg/
kg). *P < 0.05 significantly different from the 
corresponding VEH + VEH group. 
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was found on the 2nd and 3rd drug days with a signifi-
cant reversal occurring in the 1st and 2nd blocks. 
On the drug challenge test (Figure 4), rats previously 
treated with HAL (i.e., the VEH + HAL rats) made fewer 
avoidance responses than the vehicle rats treated with 
HAL for the 1st time, indicating a sensitization-like HAL 
effect. One-way ANOVA revealed that under the HAL 
(0.025 mg/kg) challenge condition, there was a main ef-
fect of group (F(2,21) = 5.122, P = 0.017). Post-hoc tests 
indicated that the VEH + VEH and DOI + HAL groups 
did not differ from each other (P = 0.904), but made sig-
nificantly more avoidances than the VEH + HAL group 
(P = 0.046 and 0.033, respectively), indicating that pre-
treatment of DOI attenuated the long-term repeated HAL 
effect. Under the CLZ (5.0 mg/kg) challenge condition, 
the prior CLZ-treated rats tended to make more avoid-
ances than the vehicle rats treated with CLZ for the 1st 
time, although the overall effect failed to reach a signif-
icant level (F(2,22) = 2.103, P = 0.148). Pretreatment of 
DOI failed to change the long-term repeated CLZ effect 
(with there being no significant difference between the 
VEH + CLZ and DOI + CLZ, P > 0.72). 
Results from the above experiments suggest that pre-
treatment of DOI, but not QUI, attenuated the long-term 
repeated HAL effect on avoidance, whereas pretreat-
ment of QUI, but not DOI, potentiated the long-term re-
peated CLZ effect. To examine whether this conclusion 
holds if data from both experiments were combined, we 
conducted two separate one-way ANOVAs for the com-
bined HAL groups (i.e., VEH + VEH challenged with 
HAL, VEH + HAL, QUI + HAL, and DOI + HAL) and 
the combined CLZ groups (i.e., VEH + VEH challenged 
with CLZ, VEH + CLZ, QUI + CLZ, and DOI + CLZ). 
Results were consistent with the analyses presented 
above (Figure 5). Under the HAL challenge condi-
tion, the VEH + HAL group made significantly fewer 
Figure 3. Effects of pretreatment 
of DOI on acute haloperidol 
and clozapine-induced avoid-
ance disruption. Data are mean 
(+SEM) numbers of avoidance 
responses of the five groups of 
rats on the last CAR training day 
(predrug), three drug test days 
(days 1 to 3) and two drug-free 
test days (drug-free CS-only and 
drug-free retraining). * < 0.05 
significantly different from the 
VEH + VEH group; #P < 0.05 
significantly different from the 
VEH + CLZ group. 
Figure 4. Effects of pretreatment of DOI on repeated effect of haloperidol and clozapine treatment on avoidance responding. Data 
are mean (+SEM) numbers of avoidance responses on the challenge test day. Rats that were previously treated with either double 
vehicles (n = 4), vehicle plus haloperidol (0.05 mg/kg), or DOI (2.5 mg/kg) plus haloperidol (0.05 mg/kg) were challenged with 
haloperidol (0.025 mg/kg). Rats that were previously treated with either double vehicles (n = 5), vehicle plus clozapine (10.0 mg/
kg), or DOI (2.5 mg/kg) plus clozapine (10.0 mg/kg) were challenged with clozapine (5.0 mg/kg). *P < 0.05 significantly different 
from the corresponding VEH + VEH group; #P < 0.05 significantly different from the VEH + HAL group.
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avoidances than the VEH + VEH group (Tukey’s HSD, 
P = 0.003), and the DOI + HAL group made signifi-
cantly more avoidances than the VEH + HAL group 
(P = 0.027). Under the CLZ condition, the VEH + VEH 
group did not differ significantly from the VEH + CLZ 
group (P = 0.103), but did make significantly fewer 
avoidances than the QUI + CLZ group (P = 0.003). 
Experiment 3: Effects of QUI and DOI pretreatment  
on HAL and CLZ suppressive effect on motor  
activity in the CAR
Both HAL and CLZ suppressed motor activity and 
inter-compartment crossings of well-trained rats in the 
CAR boxes. Pretreatment of QUI and DOI exhibited a 
strong attenuation effect on HAL and CLZ, respectively 
(Figure 6a, b). On the motor activity, a split-plot ANOVA 
revealed a main effect of group (F(4,29) = 53.053, 
P < 0.001), session (F(2,58) = 13.525, P < 0.001), and 
group × session interaction (F(8,58) = 4.754, P < 0.001). 
Individual one-way ANOVA on each drug day showed 
a main effect of group (P < 0.001). Post-hoc tests indi-
cated that all drug groups were less active than the 
VEH + VEH group on the drug test days (all P < 0.001) 
except on day 1, when the QUI + HAL group did 
not differ significantly from the VEH + VEH group 
(P = 0.338). In addition, the QUI + HAL group was sig-
nificantly more active than the VEH + HAL group 
on day 1 (P = 0.005) and day 3 (P = 0.029), but not on 
day 2 (P = 0.385). The DOI + CLZ group was signifi-
cantly more active than the VEH + CLZ group only on 
day 2 (P = 0.003), but not on days 1 (P = 0.289) and 3 
(P = 0.177). 
On the number of crossings, a split-plot ANOVA 
revealed a main effect of group (F(4,29) = 16.797, 
P < 0.001), session (F(2,58) = 13.642, P < 0.001), and 
group × session interaction (F(8,58) = 3.738, P = 0.001). 
Individual one-way ANOVA on each drug day showed 
a main effect of group (P < 0.001) with the VEH + HAL 
and VEH + CLZ groups showing significantly fewer 
crossings than the VEH + VEH group on every test day 
(P < 0.05). Also, the QUI + HAL group made signif-
icantly more crossings than the VEH + HAL group on 
day 1 (P = 0.038), but not on day 2 (P = 0.454) or three 
(P = 0.332). The DOI + CLZ group made significantly 
more crossings than the VEH + CLZ group only on 
day 2 (P = 0.003), but not on day 1 (P = 0.235) and day 3 
(P = 0.245). 
Experiment 4: Effects of QUI and DOI pretreatment on 
OLZ-induced avoidance disruption
OLZ 1.0 mg/kg suppressed avoidance respond-
ing on the first drug day and progressively enhanced 
its suppression over the 3-day period (Figure 7). A 
split-plot ANOVA revealed a main effect of OLZ 
(F(4,37) = 11.154, P < 0.001), a main effect of session 
(F(2,74) = 8.558, P < 0.001), but no OLZ × session inter-
action (F(8,74) = 0.943, P = 0.487). Individual one-way 
ANOVA showed that the drug groups made signifi-
cantly fewer avoidances than the VEH + VEH group on 
each drug day (P = 0.035–0.001) except on day 1, when 
the QUI + OLZ group (P = 0.262) and the DOI + OLZ 
group (P = 0.053) were not significantly different from 
the VEH + VEH group. 
The analysis of within-session patterns of avoid-
ance responding on drug days 1 and 2 revealed that the 
VEH + OLZ group made significantly fewer avoidances 
than the VEH + VEH group in every block on both days 
(P < 0.034). In contrast, the QUI + OLZ group was only 
significantly different from the VEH + VEH group in 
the last block on day 2 (P = 0.033). Furthermore, the 
QUI + OLZ group also made more avoidances than the 
VEH + OLZ group in the 2nd block on day 2 (P = 0.019), 
suggesting that pretreatment of QUI significantly atten-
uated the avoidance disruptive effect of OLZ. 
On the drug challenge test (Figure 8), rats previ-
ously treated with VEH + OLZ made fewer avoid-
ances than the VEH + VEH rats. Independent sam-
ples t tests showed a significant group difference 
between the VEH + VEH and VEH + OLZ groups 
(t(15) = 2.524, P = 0.023), a finding consistent with our 
Figure 5. Combined effects of 
pretreatment of quinpirole and 
DOI on repeated effect of hal-
operidol and clozapine treat-
ment on avoidance responding. 
Data are mean (+SEM) numbers 
of avoidance responses on the 
drug challenge test of the eight 
groups of rats combined from 
Experiment 1 and 2. *P < 0.05 
significantly different from the 
corresponding VEH + VEH 
group; #P < 0.05 significantly 
different from the VEH + HAL 
group.
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previous work (Li et al. 2009a; Mead and Li 2009). Both 
QUI and DOI pretreatment attenuated the long-term 
repeated OLZ effect. However, overall group differ-
ence was only marginally significant (overall group 
difference: F(4,41) = 2.258, P  = 0.081). To further ex-
amine the pretreatment effect of QUI and DOI, we an-
alyzed the within-session pattern of avoidance re-
sponding on the drug memory test day (data not 
shown). The only significant group differences were 
noted between the VEH + OLZ group and one of the 
two QUI pretreated groups in the 2nd block (one-
way ANOVA: F(4,41) = 3.204, P = 0.023; Tukey’s 
Figure 6. Effects of pretreat-
ment of quinpirole and DOI 
on haloperidol and clozap-
ine-induced motor suppres-
sion without CAR test. a) Mo-
tor activity (mean number of 
photobeam breaks), and b) 
mean number of crossings of 
the five groups of rats on the 
last CAR training day (pre-
drug), three drug test days 
(days 1 to 3), and two drug-
free test days (drug-free CS-
only and drug-free retrain-
ing). They were either treated 
subcutaneously with dou-
ble vehicles, vehicle plus hal-
operidol (0.05 mg/kg), or 
clozapine (10.0 mg/kg), or 
quinpirole (1.0 mg/kg) plus 
haloperidol (0.05 mg/kg), or 
DOI (2.5 mg/kg) plus clozap-
ine (10.0 mg/kg). *P < 0.05 
significantly different from 
the VEH + VEH group; 
#P < 0.05 significantly differ-
ent from the VEH + HAL or 
VEH + CLZ group.
Figure 7. Effects of pretreat-
ment of quinpirole and DOI 
on acute olanzapine-induced 
avoidance disruption. Data 
are mean (+SEM) numbers of 
avoidance responses of the 
five groups of rats on the last 
CAR training day (predrug), 
three drug test days (days 1 to 
3), and two drug-free test days 
(drug-free CS-only and drug-
free retraining). *P < 0.05 sig-
nificantly different from the 
VEH + VEH group.
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HSD post hoc: P = 0.042 vs. QUI + OLZ; P = 0.036 vs. 
QUI + DOI + OLZ), but not to the DOI pretreated group 
(P = 0.095), suggesting that QUI pretreatment is more 
efficacious than DOI in attenuating the long-term re-
peated OLZ effect. 
Discussion
The present study demonstrates interesting dissoci-
ated dopamine and serotonin receptor mechanisms un-
derlying acute and repeated effects of HAL, CLZ, and 
OLZ on avoidance responding—a validated behav-
ioral measure of antipsychotic efficacy (Wadenberg and 
Hicks 1999). Table 1 summarizes the possible receptor 
mechanisms as identified in the present study. 
HAL is a typical antipsychotic with strong dopamine 
D2 receptor antagonism and low 5-HT2A/2C antagonism 
(Miyamoto et al. 2005). It is not surprising to see that 
QUI, a dopamine D2/3 agonist, but not DOI, a mixed 
5-TH2A/2C agonist, was able to reverse the avoidance 
disruptive effect of HAL (a simple agonist–antagonist 
interaction). This finding confirms that HAL disrupts 
avoidance responding primarily by blocking D2 recep-
tors (Wadenberg et al. 2001b) and is consistent with pre-
vious work showing that compounds (e.g., l-dopa) that 
increase endogenous dopamine activity can reverse an-
tipsychotic-induced disruption of avoidance respond-
ing (Davies and Redfern 1974; Seiden and Hanson 1964; 
Seiden and Peterson 1968). It is also in agreement with 
other findings showing that QUI and HAL counter-
act each other in a variety of behavioral tasks, e.g., cat-
alepsy (Ninan and Kulkarni 1999), prepulse inhibition 
(Caine et al. 1995; Wan and Swerdlow 1993), and psy-
chogenic polydipsia (Amato et al. 2008). 
CLZ and OLZ are potent 5-HT2A/2C receptor antag-
onists and relatively weaker dopamine D2 antagonists 
(Meltzer et al. 2003; Meltzer et al. 1989), but to what ex-
tent each receptor action contributes to their disrup-
tive effect on avoidance responding has not been stud-
ied. For OLZ, previous studies suggest that blockade 
of dopamine D2 receptors in the striatum is an integral 
component (Olsen et al. 2008; Wadenberg et al. 2001b). 
Our finding that QUI attenuated the disruptive effect of 
OLZ is consistent with those studies. However, whether 
OLZ’s antagonist action on 5-HT2A/2C receptors also 
contributes to its avoidance disruption is not known. 
Based on the evidence that adjunct treatment with se-
lective 5-HT2A receptor antagonists to low doses of do-
pamine D2 blocking compounds, enhances the antipsy-
chotic-like suppression of CAR in rats (Wadenberg et al. 
1996), we can assume that OLZ’s 5-HT2A receptor antag-
onism may contribute to its disruption on CAR. Given 
that 5-HT2C agonism is known to exert an antipsychotic-
like suppression on CAR (Wadenberg and Hicks 1999), 
we speculate that OLZ’s antagonism on 5-HT2C recep-
tors may actually lessen its disruptive effect on CAR via 
D2 and 5-HT2A antagonism mechanisms. Therefore, the 
lack of DOI reversal effect on OLZ could be explained 
by DOI’s agonist action on 5-HT2C which may have 
masked its reversal effect on OLZ via 5-HT2A recep-
tors. Thus, in the case of OLZ, it appears that its avoid-
ance disruptive effect is mainly mediated by its D2 and 
5-HT2A antagonism. Its 5-HT2C antagonism may possi-
Figure 8. Effects of pretreatment 
of quinpirole and DOI on repeated 
effect of olanzapine treatment on 
avoidance responding. Data are 
mean (+SEM) numbers of avoid-
ance responses on the drug chal-
lenge test. *P < 0.05 significantly 
different from the VEH + VEH 
group based on the independent 
samples t test.
Table 1. Possible receptor mechanisms underlying acute and repeated effect of haloperidol, clozapine, and olanzapine treatment 
Antipsychotic drugs Haloperidol Clozapine Olanzapine
Acute effect D2  5-HT2A/2C  D2 
Repeated effect 5-HT2A/2C  D2  D2 and 5-HT2A/2C (to a lesser extent) 
54 li, sun, Zh a n g, & hu i n Ps y c ho P ha r m a c o l o g y  212 (2010) 
bly lessen its avoidance effect. This notion is also con-
sistent with other evidence showing that 5-HT2C antag-
onism is functionally opposed to 5-HT2A antagonism 
with regard to antipsychotic action (Meltzer 2002). More 
work employing more selective 5-HT2A and 5-HT2C is 
needed validate this conclusion. 
Based on their receptor binding profiles (Miyamoto 
et al. 2005) as well as findings from our maternal be-
havior work (Zhao and Li 2009), we hypothesized that 
pretreatment of DOI, but not QUI would attenuate 
acute CLZ-induced disruption on avoidance respond-
ing. Results confirm this hypothesis. The lack of an ef-
fect of QUI on the acute effect of CLZ is similar to what 
we observed in our maternal behavior study (Zhao and 
Li 2009), and suggests that its D2 antagonism may not 
play an important role in its acute effect on avoidance 
responding. This conclusion is consistent with the ob-
servation that although CLZ at 10.0 mg/kg causes 50% 
inhibition of avoidance responding, it only produces 
25% dopamine D2 receptor occupancy (Olsen et al. 
2008), far less than what is required to achieve its clin-
ical effect (Kapur et al. 2000). Others also reported that 
DOI at 10 mg/kg reversed the avoidance disruptive ef-
fect of 10 mg/kg CLZ (Browning et al. 2005), suggest-
ing the reversal effect of DOI on CLZ is quite robust and 
is a generalized effect. Because CLZ has dual action on 
both 5-HT2A and 5-HT2C receptors, and DOI is nonselec-
tive for 5-HT2A versus 5-HT2C receptors, it is impossible 
to determine which exact receptor action is responsible 
for DOI’s reversal effect and CLZ’s avoidance disrup-
tive effect. There are good reasons to speculate that CLZ 
may disrupt avoidance responding by primarily antag-
onizing 5-HT2A receptor, as opposed to 5-HT2C. Firstly, 
5-HT2C receptor agonists (e.g., WAY-163909, mCPP, D-
LSD) are shown to possess a property of suppressing 
avoidance responding (Grauer et al. 2009; Wadenberg 
and Hicks 1999). If DOI works by antagonizing CLZ-in-
duced blockade of 5-HT2C receptors, we would expect 
pretreatment of DOI to potentiate the disruptive of CLZ, 
as opposed to reverse it. Secondly, selective 5-HT2C re-
ceptor agonists are generally ineffective in counteract-
ing CLZ. For example, Ro 60-0175 (3 mg/kg), a selec-
tive 5-HT2C receptor agonist is incapable of attenuating 
CLZ (20 mg/kg)—induced dopamine release in rat me-
dial prefrontal cortex, whereas DOI (2.5 mg/kg) is ca-
pable of achieving such an effect (Ichikawa et al. 2001). 
Thirdly, many behavioral and molecular effects of DOI 
are found to be mediated by its antagonism on 5-HT2A 
receptors, not on 5-HT2C receptors. For example, DOI-
induced effects on locomotor activity, drug discrimi-
nation, head-twitch response, and prepulse inhibition 
(PPI) of acoustic startle are antagonized by 5-HT2A-se-
lective antagonist (e.g., M100907) but not by selective 
5-HT2C/2B antagonists (e.g. SB 200,646A, SB 206,553, and 
SER-082) (Halberstadt et al. 2009; Schreiber et al. 1995; 
Sipes and Geyer 1995, 1997; Smith et al. 2003), and re-
peated DOI administration induces significant changes 
in binding in 5-HT2A receptors but not 5-HT2C receptors 
(Smith et al. 1999). 
At the behavioral level, we observed that the patterns 
of reversal effects of QUI and DOI are fairly consistent 
with their reversal effects on HAL- and CLZ-induced mo-
tor suppression (Figure 6). It is thus tempting to suggest 
that QUI and DOI attenuated HAL- and CLZ-induced 
avoidance disruption by increasing motor function. This 
view may be too simplistic because the increased mo-
tor activity and number of inter-compartment crossings 
may reflect other psychological processes, such as an in-
crease in arousal and attention, or an increase in motiva-
tion in responding to stimuli. The motor function view 
is also difficult in explaining why QUI failed to attenu-
ate the effect of CLZ and DOI failed to attenuate the ef-
fects of HAL, as well as why the combination of QUI and 
DOI also failed to attenuate the effect of OLZ. It is also in-
compatible with the findings that DOI at this dose range 
decreases, not increases, motor activity in rats (Elliott et 
al. 1990; Granoff and Ashby 1998; Hawkins et al. 2008; 
Hillegaart et al. 1996; Krebs-Thomson and Geyer 1996) 
and that pretreatment of DOI can reduce neuroleptic-in-
duced catalepsy (presumably increasing motor function) 
(Wadenberg and Ahlenius 1995). The additional finding 
that QUI at 1.0 mg/kg had little effect on avoidance re-
sponding by itself, whereas DOI at 2.5 mg/kg actually 
suppressed avoidance (see Table 2) is also inconsistent 
with the general motor function view. 
In our previous studies and the present one, we have 
observed that rats that have been previously treated 
with HAL and OLZ make significantly fewer avoidance 
responses than rats treated with these drugs for the first 
time in a later drug challenge test (Li et al. 2007, 2009a; 
Mead and Li 2009). Interestingly, CLZ appeared to pro-
duce an opposite effect: rats previously treated with 
CLZ tended to make more avoidances than CLZ-naïve 



















Table 2. The effect of QUI and DOI treatment alone on avoid-
ance responding 
  Predrug                  Testa 
QUI-1.0 mg/kg (n = 12)  27.64 ± 0.897 22.64 ± 3.082
DOI-2.5 mg/kg (n = 15)  28.07 ± 0.679 8.73 ± 2.205*
Rats from experiment 3 were first retrained in a 30-trial CAR 
session to reacquire avoidance responding. Only those that 
reached the retraining criterion (>70% avoidance responses) 
in that retraining session were used in this follow-up test. 
Rats tested with QUI-1.0 mg/kg consisted of rats that were 
treated with either vehicle, HAL or QUI + HAL in experi-
ment 3. Rats tested with DOI-2.5 mg/kg consisted of rats 
that were treated with vehicle, CLZ or DOI + CLZ in exper-
iment 3. 
* P < 0.001 significantly different from the predrug condition 
a. QUI (1.0 mg/kg, s) and DOI (2.5 mg/kg, s) were adminis-
tered 40 min before a 30-trial CAR test
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et al. 2007a, b; Villanueva and Porter 1993), as Sanger 
(1985) also reported that tolerance developed rapidly 
to the avoidance disruptive effect of CLZ with repeated 
administration over 4 days. The new findings are on the 
distinct receptor mechanisms behind the sensitization 
and tolerance-like effects. Our results indicate that the 
repeated effect of HAL may be mediated by its action on 
5-HT2A/2C receptor system, whereas the repeated effect 
of OLZ and CLZ may be mediated by their action on 
D2/3 receptor system. Given the fact that HAL is also a 
5-HT2A receptor inverse agonist (Weiner et al. 2001), and 
repeated HAL treatment causes a reduction in 5-HT2A 
receptor mRNA expression in various limbic regions 
(Buckland et al. 1997), it is possible that HAL causes a 
sensitization-like effect in this model by down-regulat-
ing 5-HT2A receptor. DOI may decrease this long-term 
impact of HAL by counteracting its effect on 5-HT2A re-
ceptor. This idea is also consistent with the well-known 
augmentation effect of 5-HT2A antagonism on HAL. For 
example, 5-HT2A-selective antagonist M100907 is shown 
to potentiate HAL-induced dopamine release in the me-
dial prefrontal cortex (Bonaccorso et al. 2002), to reduce 
the reward-attenuating effect of HAL (Benaliouad et al. 
2007), and to potentiate the avoidance disruptive effect 
of HAL (Wadenberg et al. 2001a). The repeated effect of 
CLZ and OLZ via D2/3 receptor systems could be under-
stood in the context of their known long-term effect on 
D2/3 receptors (Atkins et al. 1999; Kapur et al. 2003; Mo-
ran-Gates et al. 2006). One important task for future re-
search is to figure out how antipsychotics induce brain 
changes through these and other receptor systems (e.g., 
5-HT1A, D1, D4, etc.) and how important different recep-
tor mechanisms are to the clinical antipsychotic action 
of a drug. 
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